Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

RABL6A Is an Essential Driver of MPNSTs that Negatively Regulates the RB1 Pathway and Sensitizes Tumor Cells to CDK4/6 Inhibitors

21 Feb 2020

Abstract excerpt

Abstract Purpose: Malignant peripheral nerve sheath tumors (MPNST) are deadly sarcomas that lack effective therapies. In most MPNSTs, the retinoblastoma (RB1) tumor suppressor is disabled by hyperactivation of cyclin-dependent kinases (CDK), commonly through loss of CDK-inhibitory proteins such as p27(Kip1). RABL6A is an inhibitor of RB1 whose role in MPNSTs is unknown. To gain insight into MPNST development and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer-related Molecular Pathways
Share to Neuroblastoma Research and Treatments
Share to Neurofibromatosis and Schwannoma Cases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 32086342
DOI: 10.1158/1078-0432.ccr-19-2706

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

RABL6A Is an Essential Driver of MPNSTs that Negatively Regulates the RB1 Pathway and Sensitizes Tumor Cells to CDK4/6 InhibitorsPMID 32086342Read ↗

Oncogenic RABL6A promotes NF1-associated MPNST progression in vivoSemantic proximity Read ↗

RABL6A Regulates Schwann Cell Senescence in an RB1-Dependent MannerSemantic proximity Read ↗

PRMT5 is Frequently Upregulated and a Potential Therapeutic Target in MTAP-deficient Malignant Peripheral Nerve Sheath TumorsSemantic proximity Read ↗

CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon restoration of RB function in malignant peripheral nerve sheath tumorsSemantic proximity Read ↗

FOXM1, MEK, and CDK4/6: New targets for MPNST therapySemantic proximity Read ↗

RRM2 as a novel prognostic and therapeutic target of NF1-associated MPNSTSemantic proximity Read ↗

Malignant peripheral nerve sheath tumor in children: A clinicopathologic and molecular study with parallels to the adult counterpart.Semantic proximity Read ↗

RABL6A Promotes G1–S Phase Progression and Pancreatic Neuroendocrine Tumor Cell Proliferation in an Rb1-Dependent MannerSemantic proximity Read ↗

An ShRNA Screen Identifies MEIS1 as a Driver of Malignant Peripheral Nerve Sheath Tumors.Semantic proximity Read ↗

CDK6 coordinates JAK2V617F mutant MPN via NF-κB and apoptotic networksSemantic proximity Read ↗

Loss of PRC2 function promotes MPNST pathogenesis.Semantic proximity Read ↗

Intratumoral plasma cells mediate CD8+ T cell infiltration and successful immune checkpoint blockade therapy in <i>de novo</i> MPNSTsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.